111In DTPA Pro1 Tyr4 - bombesin

Drug Profile

111In DTPA Pro1 Tyr4 - bombesin

Alternative Names: 111In DTPA Pro1, Tyr4 - BN

Latest Information Update: 12 Sep 2003

Price : $50

At a glance

  • Originator Mallinckrodt Medical
  • Class Neuropeptides; Peptide hormones; Radiopharmaceutical diagnostics; Venoms
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 01 Nov 2000 Mallinckrodt acquired by Tyco International
  • 26 Oct 2000 Preclinical development for Solid tumours (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top